“Notably, Sarepta aims to broaden use of Elevidys to include patients who can no longer walk, a group whose disease is more advanced. That request “is more of a stretch,” Lugo wrote. “We would not be surprised if these patients are excluded from the expanded label.”
——————————/
Does that mean Non Ambulant DMD people won’t be able to access Elevidys ?
Leaves the door open for Atl 1102 to work its magic
Imo: FDA will do as Lugo wrote ..
“Notably, Sarepta aims to broaden use of Elevidys to include...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.5¢ |
Change
-0.002(2.30%) |
Mkt cap ! $76.63M | |||
| Open | High | Low | Value | Volume |
| 9.0¢ | 9.2¢ | 8.5¢ | $81.76K | 928.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 189228 | 8.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.9¢ | 10352 | 1 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
9.0¢ |
Change
-0.002 ( 2.27 %) |
||||
| Open | High | Low | Volume | ||
| 9.0¢ | 9.0¢ | 9.0¢ | 1 | ||
| Last updated 10.35am 06/06/2024 ? | |||||
| PER (ASX) Chart |